A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02152605 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

498

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: UMEC/VI
DRUG: Placebo

Sponsor

GlaxoSmithKline